Preserving the submandibular gland during neck dissection for oral cancer patients
Official title: Submandibular Gland Preservation During Neck Dissection for Oral Squamous Cell Carcinoma
Run by Peking University · NCT03385720 · Data updated 2026-11-12
This study tests if keeping the submandibular gland during surgery helps early-stage oral cancer patients live longer compared to those who have it removed.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | Any age to 90 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Peking University Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | December 5, 2017 |
| Main results expected | December 2023 |
| Study ends | December 2030 |
| Registry record updated | March 30, 2023 |
| Trial ID | NCT03385720 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients diagnosed with early-stage oral squamous cell carcinoma (T1N0 and T2N0).
✕Probably not a fit
Patients with cancer of the floor of the mouth will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effects of preserving the submandibular gland during neck dissection in patients with early-stage oral squamous cell carcinoma. Participants are randomly assigned to either an experimental group, where the gland is preserved, or a control group, where it is removed. The study aims to compare survival and mortality rates between the two groups to assess the benefits of gland preservation. The trial focuses on patients with primary oral cancer, specifically those classified as T1N0 and T2N0.
Why it matters
Potential benefit: If successful, this approach could improve patient outcomes by reducing complications associated with gland removal.
How similar studies have gone: While there may be studies on neck dissection techniques, this specific approach to gland preservation is relatively novel and has not been widely tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Primary oral squamous cell carcinoma of early stage (T1N0 and T2N0). Exclusion Criteria: Cancer of the floor of the mouth.
Where it's running
-
Peking University School of Stomatology
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Jia-Zeng Su, Dr.
- Email: sujiazeng@163.com
- Phone: 86 10 82195992
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Intratumoral fluorescent nivolumab before surgery in head and neck cancer
This study tests injecting fluorescently labeled nivolumab directly into head and neck tumors to see if it is safe and whether it reaches nearby lymph nodes before surgical removal.
-
AI-assisted prehabilitation to help oral cancer patients return to work
This trial will test an AI-assisted prehabilitation program to help adults with oral cancer reduce physical and emotional problems and return to work.
-
AI tool to measure jaw, neck, and shoulder movement for oral cancer care
This project tests an AI system that automatically measures jaw, neck, and shoulder movement for people with or recovering from oral cancer and compares its readings to manual measurements.
-
Dezocine versus nalbuphine with sufentanil for pain control after oral cancer surgery with free-flap reconstruction
This will see if adding dezocine or nalbuphine to sufentanil reduces pain and complications for adults undergoing oral cancer surgery with free-flap reconstruction.
-
Hydrogen water oral care after free flap reconstruction for oral cancer
A randomized trial tests whether hydrogen water oral care helps reduce inflammation and pain and improve oral bacteria after surgery for oral cancer.
-
Monitoring circulating tumor cells in postoperative ENE-positive oral cavity cancer after adjuvant concurrent chemoradiation.
This trial will test whether regular blood monitoring of circulating tumor cells and adding extended low-dose oral chemotherapy can help people with ENE-positive oral cavity squamous cell carcinoma after surgery and adjuvant concurrent chemoradiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.